|Mr. John H. Johnson||CEO & Director||1.13M||N/A||1958|
|Dr. Fredric Cohen||Chief Medical Officer||784.11k||N/A||1965|
|Mr. Richard S. Kollender CPA, CPA, M.B.A.||Pres & CFO||N/A||N/A||1969|
|Dr. Per Marin M.D., Ph.D.||Founder and Sr. Clinical Advisor||N/A||N/A||N/A|
|Mr. Peter J. Valentinsson||Sr. VP of Global Technical Operations||N/A||N/A||N/A|
|Mr. Stephen J. Long||Chief Legal Officer & Company Sec.||N/A||N/A||1966|
|Mr. Brian Conner||Chief Compliance Officer||N/A||N/A||N/A|
|Mr. Dave Bonnell||Sr. VP of Sales||N/A||N/A||N/A|
|Ms. Emily Doyle||Chief HR Officer||N/A||N/A||N/A|
|Mr. Scott L. Wilhoit||Chief Commercial Officer||N/A||N/A||1963|
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs in the United States. The company offers Keveyis, an oral carbonic anhydrase inhibitor to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. Its clinical-stage product candidates include Recorlev, a cortisol synthesis inhibitor, which is in Phase III clinical trials for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somatostatin analog that has completed Phase II clinical trial for the treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is based in Trevose, Pennsylvania.
Strongbridge Biopharma plc’s ISS Governance QualityScore as of July 1, 2021 is 6. The pillar scores are Audit: 8; Board: 6; Shareholder Rights: 4; Compensation: 8.